290 related articles for article (PubMed ID: 21884439)
1. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
Goel S; Simes RJ; Beith JM
Asia Pac J Clin Oncol; 2011 Sep; 7(3):276-80. PubMed ID: 21884439
[TBL] [Abstract][Full Text] [Related]
2. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab.
Knobloch K; Tepe J; Lichtinghagen R; Luck HJ; Vogt PM
Int J Cardiol; 2008 Mar; 125(1):113-5. PubMed ID: 17400308
[TBL] [Abstract][Full Text] [Related]
4. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
Soker M; Kervancioglu M
Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
[TBL] [Abstract][Full Text] [Related]
6. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels.
Hong SN; Ahn Y; Yoon NS; Lee KH; Kim YS; Hwang SH; Lee SR; Kim KH; Park HW; Hong YJ; Kim JH; Jeong MH; Cho JG; Park JC; Kang JC
Am J Cardiol; 2007 Apr; 99(8):1051-4. PubMed ID: 17437726
[TBL] [Abstract][Full Text] [Related]
9. Cardiac markers (BNP, NT-pro-BNP, Troponin I, Troponin T, in female amateur runners before and up until three days after a marathon.
Frassl W; Kowoll R; Katz N; Speth M; Stangl A; Brechtel L; Joscht B; Boldt LH; Meier-Buttermilch R; Schlemmer M; Roecker L; Gunga HC
Clin Lab; 2008; 54(3-4):81-7. PubMed ID: 18630737
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
11. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
J Heart Lung Transplant; 2007 May; 26(5):516-21. PubMed ID: 17449423
[TBL] [Abstract][Full Text] [Related]
12. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F
Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery.
Rajagopalan S; Croal BL; Bachoo P; Hillis GS; Cuthbertson BH; Brittenden J
J Vasc Surg; 2008 Oct; 48(4):912-7; discussion 917. PubMed ID: 18586440
[TBL] [Abstract][Full Text] [Related]
16. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
17. Preprocedural N-terminal pro-B-type natriuretic peptide as a useful marker for predicting periprocedural myocardial injury following percutaneous coronary intervention in diabetic patients without cardiac dysfunction.
Zeng RX; Li XL; Zhang MZ; Wang XW; Guo YL; Zhu CG; Ren Y; Li S; Zhang Y; Liu G; Xu RX; Dong Q; Li JJ
Scand J Clin Lab Invest; 2015 Nov; 75(7):568-77. PubMed ID: 26203960
[TBL] [Abstract][Full Text] [Related]
18. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
19. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients.
Wang AY; Lam CW; Wang M; Chan IH; Lui SF; Zhang Y; Sanderson JE
Nephrol Dial Transplant; 2009 Jun; 24(6):1962-9. PubMed ID: 19237403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
